NCT06771674 - Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

662

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG

Pembrolizumab

Given as monotherapy.

DRUG

Nivolumab

Given in combination with chemotherapy.

DRUG

Nivolumab

Given without chemotherapy.

DRUG

Pembrolizumab

Given in combination with chemotherapy.

DRUG

Pembrolizumab

Given without chemotherapy.

Trial Locations (1)

Cardinal Health, Dublin